Targetable fusions of the FRK tyrosine kinase in ALKnegative anaplastic large cell lymphoma

G. Hu; S. Dasari; Y. W. Asmann; P. T. Greipp; R. A. Knudson; H. K. Benson; Y. Li; B. W. Eckloff; J. Jen; B. K. Link; L. Jiang; J. S. Sidhu; L. E. Wellik; T. E. Witzig; N. N. Bennani; J. R. Cerhan; R. L. Boddicker; A. L. Feldman

doi:10.1038/leu.2017.309

Targetable fusions of the FRK tyrosine kinase in ALKnegative anaplastic large cell lymphoma

G. Hu, S. Dasari, Y. W. Asmann, P. T. Greipp, R. A. Knudson, H. K. Benson, Y. Li, B. W. Eckloff, J. Jen, B. K. Link, L. Jiang, J. S. Sidhu, L. E. Wellik, T. E. Witzig, N. N. Bennani, J. R. Cerhan, R. L. Boddicker, A. L. Feldman

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

20 Scopus citations

Original language	English (US)
Pages (from-to)	565-569
Number of pages	5
Journal	Leukemia
Volume	32
Issue number	2
DOIs	https://doi.org/10.1038/leu.2017.309
State	Published - Feb 1 2018

Funding

This study was supported by research funding from Amgen Inc. Geoff Smith of Amgen Inc. and Jonathan Latham, a medical writer supported by funding from Amgen Inc., provided editorial assistance to the authors during the preparation of this manuscript. This study was supported by Award Numbers R01 CA177734 (to ALF), P30 CA15083 (Mayo Clinic Cancer Center) and P50 CA97274 (University of Iowa/Mayo Clinic Lymphoma SPORE) from the National Cancer Institute; CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS); Award Number CI-48-09 from the Damon Runyon Cancer Research Foundation (to ALF); Department of Laboratory Medicine and Pathology and Center for Individualized Medicine, Mayo Clinic; and the Predolin Foundation.

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2017.309

Cite this

Hu, G., Dasari, S., Asmann, Y. W., Greipp, P. T., Knudson, R. A., Benson, H. K., Li, Y., Eckloff, B. W., Jen, J., Link, B. K., Jiang, L., Sidhu, J. S., Wellik, L. E., Witzig, T. E., Bennani, N. N., Cerhan, J. R., Boddicker, R. L., & Feldman, A. L. (2018). Targetable fusions of the FRK tyrosine kinase in ALKnegative anaplastic large cell lymphoma. Leukemia, 32(2), 565-569. https://doi.org/10.1038/leu.2017.309

@article{f8b4960e72054b1497273b9af16c7ad7,

title = "Targetable fusions of the FRK tyrosine kinase in ALKnegative anaplastic large cell lymphoma",

author = "G. Hu and S. Dasari and Asmann, {Y. W.} and Greipp, {P. T.} and Knudson, {R. A.} and Benson, {H. K.} and Y. Li and Eckloff, {B. W.} and J. Jen and Link, {B. K.} and L. Jiang and Sidhu, {J. S.} and Wellik, {L. E.} and Witzig, {T. E.} and Bennani, {N. N.} and Cerhan, {J. R.} and Boddicker, {R. L.} and Feldman, {A. L.}",

note = "Funding Information: This study was supported by research funding from Amgen Inc. Geoff Smith of Amgen Inc. and Jonathan Latham, a medical writer supported by funding from Amgen Inc., provided editorial assistance to the authors during the preparation of this manuscript. Funding Information: This study was supported by Award Numbers R01 CA177734 (to ALF), P30 CA15083 (Mayo Clinic Cancer Center) and P50 CA97274 (University of Iowa/Mayo Clinic Lymphoma SPORE) from the National Cancer Institute; CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS); Award Number CI-48-09 from the Damon Runyon Cancer Research Foundation (to ALF); Department of Laboratory Medicine and Pathology and Center for Individualized Medicine, Mayo Clinic; and the Predolin Foundation.",

year = "2018",

month = feb,

day = "1",

doi = "10.1038/leu.2017.309",

language = "English (US)",

volume = "32",

pages = "565--569",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "2",

}

Hu, G, Dasari, S, Asmann, YW, Greipp, PT, Knudson, RA, Benson, HK, Li, Y, Eckloff, BW, Jen, J, Link, BK, Jiang, L, Sidhu, JS, Wellik, LE, Witzig, TE, Bennani, NN, Cerhan, JR, Boddicker, RL & Feldman, AL 2018, 'Targetable fusions of the FRK tyrosine kinase in ALKnegative anaplastic large cell lymphoma', Leukemia, vol. 32, no. 2, pp. 565-569. https://doi.org/10.1038/leu.2017.309

TY - JOUR

T1 - Targetable fusions of the FRK tyrosine kinase in ALKnegative anaplastic large cell lymphoma

AU - Hu, G.

AU - Dasari, S.

AU - Asmann, Y. W.

AU - Greipp, P. T.

AU - Knudson, R. A.

AU - Benson, H. K.

AU - Li, Y.

AU - Eckloff, B. W.

AU - Jen, J.

AU - Link, B. K.

AU - Jiang, L.

AU - Sidhu, J. S.

AU - Wellik, L. E.

AU - Witzig, T. E.

AU - Bennani, N. N.

AU - Cerhan, J. R.

AU - Boddicker, R. L.

AU - Feldman, A. L.

N1 - Funding Information: This study was supported by research funding from Amgen Inc. Geoff Smith of Amgen Inc. and Jonathan Latham, a medical writer supported by funding from Amgen Inc., provided editorial assistance to the authors during the preparation of this manuscript. Funding Information: This study was supported by Award Numbers R01 CA177734 (to ALF), P30 CA15083 (Mayo Clinic Cancer Center) and P50 CA97274 (University of Iowa/Mayo Clinic Lymphoma SPORE) from the National Cancer Institute; CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS); Award Number CI-48-09 from the Damon Runyon Cancer Research Foundation (to ALF); Department of Laboratory Medicine and Pathology and Center for Individualized Medicine, Mayo Clinic; and the Predolin Foundation.

PY - 2018/2/1

Y1 - 2018/2/1

UR - http://www.scopus.com/inward/record.url?scp=85042255703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042255703&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.309

DO - 10.1038/leu.2017.309

M3 - Letter

C2 - 29026208

AN - SCOPUS:85042255703

SN - 0887-6924

VL - 32

SP - 565

EP - 569

JO - Leukemia

JF - Leukemia

IS - 2

ER -

Targetable fusions of the FRK tyrosine kinase in ALKnegative anaplastic large cell lymphoma

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this